Clinical trials: Anlotinib
Locally Advanced Thyroid Gland Carcinoma
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing.
- Trial name
- NCT06482086
- Testing
- Anlotinib, Lenvatinib, Sorafenib
- Where
- China
- Volunteers
- 75 people
- Sponsor
- West China Hospital
NSCLC, Adenocarcinoma
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
Non-small cell lung cancer has the highest morbidity and mortality in China，and platinum-based chemotherapy is the standard first-line treatment for the wild-type NSCLC,however the overall survival still less than one…
- Conditions
- NSCLC, Adenocarcinoma, Squamous Cell Carcinoma
- Trial name
- NCT03636685
- Testing
- Anlotinib combined with pemetrexed and carboplatin, phase I, Anlotinib combined with paclitaxel and carboplatin, phase I, Anlotinib combined with pemetrexed and carboplatin, phase II
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line…
- Trial name
- NCT03906058
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
Epidermal growth factor receptor Tyrosine kinase inhibitor (EGFR TKI) have been approved to treat NSCLC harboring EGFR mutation as first-line therapy.
- Trial name
- NCT03461185
- Testing
- EGFR-TK Inhibitor, Anti-Angiogenic Drugs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
Non Clear Cell Renal Carcinoma
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer.
- Trial name
- NCT05220267
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Platinum-resistant Ovarian Cancer
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
The goal of this clinical trial is to evaluate the treatment of topotecan hydrochloride capsules combined with anlotinib hydrochloride capsules in Patients with platinum-resistant recurrent epithelial ovarian cancer.
- Trial name
- NCT05736952
- Testing
- Oral Topotecan Combined With Anlotinib
- Where
- China
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Carcinoma, Non-Small-Cell Lung
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
Concurrent or sequential chemoradiotherapy has been recommended as the standard treatment for locally advanced and unresectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT05306847
- Testing
- Sintilimab, Anlotinib
- Volunteers
- 93 people
- Sponsor
- Peking Union Medical College Hospital
TNBC, Triple Negative Breast Cancer
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
This study is a single-arm, multicenter, prospective phase II clinical trial designed to evaluate the efficacy and safety of QL1706 in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for…
- Trial name
- NCT07601178
- Testing
- TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Uterine Cervical Neoplasms
Chemotherapy With Anlotinib in Advanced Cervical Cancer
STUDY HYPOTHESIS: The primary hypothesis is whether chemotherapy with Anlotinib improves overall survival in advanced cervical cancer. TRIAL DESIGN: The study is a prospective, single-arm, observational clinical study.
- Trial name
- NCT04695535
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yang Shen
Endometrial Cancer, Ovarian Cancer
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD).
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- AL3818 (NCT02558348)
- Testing
- AL3818
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advenchen Laboratories, LLC
SCLC, Extensive Stage, Bayesian
Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol.
- Conditions
- SCLC, Extensive Stage, Bayesian, Metronomic Chemotherapy
- Trial name
- NCT07698054
- Testing
- Toripalimab; Etoposide
- Volunteers
- 130 people
- Sponsor
- Henan Cancer Hospital
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance
This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients…
- Trial name
- NCT04316351
- Testing
- Toripalimab + Pemetrexed + Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Kidney Cancer, Renal Cell Carcinoma
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Based on different subtypes, subjects will be placed in one of three treatment groups to explore individual efficacy and safety of various treatment regimen.
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma
- Trial name
- NCT06211790
- Testing
- Anlotinib, Everolimus and Tislelizumab
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Fudan University
Soft Tissue Sarcoma
Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR)…
- Trial name
- NCT03792542
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Sarcoma,Soft Tissue
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor with an incidence of 1-2/100000. For unresectable or widely disseminated advanced STS, a combined clinical trial is the best way to obtain evidence-based…
- Trial name
- NCT04172805
- Testing
- anlotinib and toripalimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Thyroid Cancer
Anlotinib and Benmelstobart in DTC
This study is a multicenter, open-label, phase II study to evaluate the efficacy and safety of Benmelstobart in combination with Anlotinib as a second-line treatment for locally advanced or metastatic differentiated thyroid…
- Trial name
- NCT07193186
- Testing
- Anlotinib and Benmelstobart
- Volunteers
- 23 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma
This clinical study evaluates the efficacy and safety of anlotinib in patients with hepatocellular carcinoma who have progressed on lenvatinib treatment.
- Trial name
- ALTER-H-002 (NCT04080154)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
- Trial name
- NCT05866510
- Testing
- Utidelone and anlotinib
- Where
- 3 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University
Bile Duct Carcinoma, Gall Bladder Cancer
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Brief Summary: This study is for patients with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The purpose is to find out if using anti-blood vessel formation drugs after immunotherapy treatment can help…
- Conditions
- Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
- Trial name
- SAIB (NCT07025174)
- Testing
- PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University